Method for Cancer Therapy Based on Co-Administration of a Parvovirus and a Cytokine
US-2016367609-A1 · Dec 22, 2016 · US
Oncolytic HSV1 vectors and methods of using the same
US10232002B1 · US · B1
| Field | Value |
|---|---|
| Publication number | US-10232002-B1 |
| Application number | US-201314442632-A |
| Country | US |
| Kind code | B1 |
| Filing date | Nov 14, 2013 |
| Priority date | Nov 14, 2012 |
| Publication date | Mar 19, 2019 |
| Grant date | Mar 19, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Malignant tumors that are resistant to conventional therapies represent significant therapeutic challenges. An embodiment of the present invention provides an oncolytic virus capable of killing target cells, such as tumor cells. In various embodiments presented herein, the oncolytic viruses described herein are suitable for treatment of several types of cancer, including glioblastoma.
First claim
Opening claim text (preview).
What is claimed is: 1. An oncolytic herpes simplex virus deficient for a γ 1 34.5 gene comprising a nucleic acid comprising: a) a nucleotide sequence encoding N-terminal truncated human GADD34 protein, wherein the nucleotide sequence is set forth in SEQ ID NO: 2, wherein said nucleotide sequence is operably linked to an expression control sequence. 2. The oncolytic herpes simplex virus of claim 1 , wherein the expression control sequence comprises a nestin promoter or a biologically active portion thereof. 3. The oncolytic herpes simplex virus of claim 1 , wherein the expression control sequence comprises SEQ ID NO: 3. 4. The oncolytic herpes simplex virus of claim 1 , wherein the expression control sequence comprises a tumor specific promoter. 5. The oncolytic herpes simplex virus of claim 4 , wherein the tumor specific promoter is specific for colon cancer cells, breast cancer cells, melanoma cells, or protstate cancer cells. 6. The oncolytic herpes simplex virus of claim 4 , wherein the tumor specific promoter is selected from the group consisting of a CEA promoter, a Muc1 promoter, a Myb1 promoter, a Tyrosinase promoter, and a PSA promoter.
Assignees
Inventors
Classifications
Antineoplastic agents · CPC title
Herpes virus · CPC title
from mammals · CPC title
from mammals · CPC title
of bacterial origin, e.g. BAC · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10232002B1 cover?
- Malignant tumors that are resistant to conventional therapies represent significant therapeutic challenges. An embodiment of the present invention provides an oncolytic virus capable of killing target cells, such as tumor cells. In various embodiments presented herein, the oncolytic viruses described herein are suitable for treatment of several types of cancer, including glioblastoma.
- Who is the assignee on this patent?
- Brigham & Womens Hospital Inc, Ohio State Innovation Foundation, The Brigham And Womens Hospital
- What technology area does this patent fall under?
- Primary CPC classification A61K35/768. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Mar 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).